BioSenic S.A. (BIOS.BR)
- Previous Close
0.0019 - Open
0.0020 - Bid --
- Ask --
- Day's Range
0.0017 - 0.0022 - 52 Week Range
0.0012 - 0.0360 - Volume
20,001,230 - Avg. Volume
7,892,768 - Market Cap (intraday)
1.175M - Beta (5Y Monthly) -2.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date May 13, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
www.biosenic.comRecent News: BIOS.BR
View MorePerformance Overview: BIOS.BR
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOS.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOS.BR
View MoreValuation Measures
Market Cap
1.24M
Enterprise Value
27.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-259.05%
Return on Assets (ttm)
-22.77%
Return on Equity (ttm)
--
Revenue (ttm)
2.87M
Net Income Avi to Common (ttm)
-7.44M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
816k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.21M